These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 23476996)

  • 1. Use of materials derived from cattle in human food and cosmetics; reopening of the comment period. Interim final rule; reopening of the comment period.
    Food and Drug Administration, HHS
    Fed Regist; 2013 Mar; 78(42):14012-3. PubMed ID: 23476996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Establishment registration and listing for manufacturers of human cellular and tissue-based products--FDA. Proposed rule; reopening of comment period.
    Fed Regist; 1998 Dec; 63(237):68212-3. PubMed ID: 10338885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Control of communicable diseases; restrictions on African rodents, prairie dogs, and certain other animals. Interim final rule; supplement and partial reopening of comment period.
    Food and Drug Administration, HHS
    Fed Regist; 2007 Feb; 72(34):7825-6. PubMed ID: 17319058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medicare program; prospective payment system and consolidated billing for skilled nursing facilities; reopening of comment period--HCFA. Notice of reopening of comment period for interim final rule.
    Fed Regist; 1998 Nov; 63(228):65561-2. PubMed ID: 10338875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amended economic impact analysis of final rule requiring use of labeling on natural rubber containing devices--FDA. Final rule; amended economic analysis statement.
    Fed Regist; 1998 Jun; 63(104):29552-90. PubMed ID: 10179863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Registration of food facilities under the Public Health Security and Bioterrorism Preparedness and Response Act of 2002. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2005 Oct; 70(190):57505-9. PubMed ID: 16200686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estimating the impact on the food chain of changing bovine spongiform encephalopathy (BSE) control measures: the BSE control model.
    Adkin A; Webster V; Arnold ME; Wells GA; Matthews D
    Prev Vet Med; 2010 Feb; 93(2-3):170-82. PubMed ID: 19836847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of the impact of cattle testing strategies on human exposure to BSE agents in Japan.
    Tsutsui T; Kasuga F
    Int J Food Microbiol; 2006 Apr; 107(3):256-64. PubMed ID: 16388864
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human drugs and biologics; determination that informed consent is NOT feasible or is contrary to the best interests of recipients; revocation of 1990 interim final rule; establishment of new interim final rule. Food and Drug Administration, HHS. Interim final rule; opportunity for public comment.
    Fed Regist; 1999 Oct; 64(192):54180-9. PubMed ID: 11010702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bovine sera used in the manufacture of biologicals: current concerns and policies of the U.S. Food and Drug Administration regarding the transmissible spongiform encephalopathies.
    Asher DM
    Dev Biol Stand; 1999; 99():41-4. PubMed ID: 10404874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amended economic impact analysis of final rule requiring use of labeling on natural rubber containing devices--FDA. Final rule; amended economic analysis statement.
    Fed Regist; 1998 Aug; 63(168):46171-4. PubMed ID: 10182698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amended economic impact analysis of final rule requiring use of labeling on natural rubber containing devices--FDA. Final rule; amended economic analysis statement.
    Fed Regist; 1998 Sep; 63(183):50660-704. PubMed ID: 10185803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Revisions to the general safety test requirements for biological products--FDA. Direct final rule: confirmation in part and withdrawal in part.
    Fed Regist; 1998 Aug; 63(150):41718. PubMed ID: 10181723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prescription Drug Marketing Act of 1987; Prescription Drug Amendments of 1992; policies, requirements, and administrative procedures; delay of effective date; reopening of administrative record. Food and Drug Administration, HHS. Final rule; delay of effective date; reopening of administrative record.
    Fed Regist; 2000 May; 65(86):25639-41. PubMed ID: 11010689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Final report on the safety assessment of human placental protein, hydrolyzed human placental protein, human placental enzymes, human placental lipids, human umbilical extract, placental protein, hydrolyzed placental protein, placental enzymes, placental lipids, and umbilical extract.
    Nair B; Elmore AR;
    Int J Toxicol; 2002; 21 Suppl 1():81-91. PubMed ID: 12042062
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medicare program; update of ratesetting methodology, payment rates, payment policies, and the list of covered procedures for ambulatory surgical centers effective October 1, 1998; reopening of comment period and delay in adoption of the proposed rule as final--HCFA. Notice of reopening of comment period for proposed rule and delay in adoption of provisions of the proposed rule as final.
    Fed Regist; 1998 Oct; 63(190):52663-5. PubMed ID: 10185818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Skin protectant drug products for over-the-counter human use; astringent drug products; final monograph; direct final rule. Direct final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2003 Jun; 68(114):35290-3. PubMed ID: 12807133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Experimental bovine spongiform encephalopathy: detection of PrP(Sc) in the small intestine relative to exposure dose and age.
    Stack MJ; Moore SJ; Vidal-Diez A; Arnold ME; Jones EM; Spencer YI; Webb P; Spiropoulos J; Powell L; Bellerby P; Thurston L; Cooper J; Chaplin MJ; Davis LA; Everitt S; Focosi-Snyman R; Hawkins SA; Simmons MM; Wells GA
    J Comp Pathol; 2011; 145(2-3):289-301. PubMed ID: 21388635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medicaid program; state share of financial participation--HCFA. Withdrawal of interim final rule with comment.
    Fed Regist; 1991 Dec; 56(236):64195. PubMed ID: 10115766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medical devices; humanitarian use of devices--FDA. Direct final rule; withdrawal.
    Fed Regist; 1998 Jul; 63(147):40825. PubMed ID: 10181716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.